Ascendis Pharma A (ASND) Convertible Debt (2021 - 2025)

Ascendis Pharma A has disclosed Convertible Debt across 4 years of filings, most recently posting $499.8 million for Q4 2025.

• Convertible Debt for Q4 2025 came in at $499.8 million, up 2.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $499.8 million (up 2.08% YoY), and the FY2025 annual result was $499.8 million, up 2.08% from the prior year.
• Convertible Debt came in at $499.8 million for Q4 2025 at Ascendis Pharma A, up from $489.6 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $499.8 million in Q4 2025 to a low of $188.0 million in Q4 2021.
• The 4-year median for Convertible Debt is $448.5 million (2024), against an average of $396.2 million.
• Across the five-year window, Convertible Debt soared 116.58% in 2022 and gained 2.08% in 2025, its largest moves.
• Ascendis Pharma A's Convertible Debt stood at $188.0 million in 2021, then soared by 116.58% to $407.3 million in 2022, then increased by 20.22% to $489.6 million in 2024, then gained by 2.08% to $499.8 million in 2025.
• The last three Convertible Debt figures came in at $499.8 million (Q4 2025), $489.6 million (Q4 2024), and $407.3 million (Q4 2022), per Business Quant data.